PharmaMar earned 3.5 million euros in the first half of 2024. This figure represents a 45.3% drop compared to the same period last year. The pharmaceutical company explained to elEconomista.es that this decrease is due to the entry of Yondelis generics into the market and increased investment in the development of new treatments, especially in phase III clinical trials. In addition, the company recorded a negative gross operating result (EBITDA) of 803 million, compared to 4.1 million registered a year earlier.
Corporation income 80.8 million until Juneup 1% from the first six months of 2023 (80.2 million). PharmaMar’s main driver is oncology, with a turnover of 42 million, down 3%. There are two products that attract most attention, concentrating most of the revenue. About Yondelis, whose sales fell by 30.9%, increasing from 14.2 million to 9.8 million.
Also found Zepzeltsaits star cancer therapy, the income of which is divided in half. Royalty turnover increased by 16% to 26.5 million. This includes sales of this drug in the United States – where it is marketed by Jazz Pharmaceutical – of which 24.2 million were registered, up 15% compared to the first six months of 2023. It should be noted that the total royalty income was 2.3 million, corresponding to the fees of Yondelis in the North American country and Japan.
Parallel, one-time lab sales fell 4%increasing from 12.8 million to 12.3 million. Accounts for this chapter are based on licensing agreements related to lurbinectidine.
Attention in the field of research and development (R&D)The pharmaceutical company allocated 51.3 million in the first half of the year, which is 10% more than the same period last year (46.6 million).
On the other hand, the laboratory registered a debt in the amount of 36.3 million in the first semester, compared to the 39.8 million with which it closed the first half of 2023.
In this sense, PharmaMar ended this year with positive net cash 103.3 millions compared to 128.7 million reached at the end of last year. Specifically, 25.4% less.